Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.32 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22656748 | 1.00 | KDM4E (0.33) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL14874483 | 0.89 | MAP3K7 (0.30) | MAP3K7TAB1 | |
| SCHEMBL25412095 | 0.86 | MAP3K7 (0.30) | MAP3K7TAB1 | |
| SCHEMBL29375642 | 0.79 | MAP3K7 (0.32) | MAP3K7TAB1 | |
| SCHEMBL6554654 | 0.79 | MAPT (0.45) | KDM4EALDH1A1 | |
| Histidine SCHEMBL16879895 | 0.78 | SLC7A5 (0.38) | ALDH1A1HSD17B10 | |
| Histidinol SCHEMBL28190716 | 0.78 | ALPI (0.31) | — | |
| SCHEMBL26762635 | 0.77 | MAP3K7 (0.30) | MAP3K7TAB1 | |
| SCHEMBL704416 | 0.77 | S1PR2 (0.36) | — | |
| SCHEMBL22367860 | 0.77 | S1PR2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0688210-B1 | USE OF CARNOSINE IN COMBINATION WITH UROCANIC ACID FOR TREATMENT OF PHOTODERMATOSES | BEIERSDORF AG (DE) | 2004-02-25 | — | — | EP | claimed |
| EP-0688210-A1 | USE OF CARNOSINE OR A COMBINATION WITH UROCANIC ACID FOR TREATMENT OF PHOTODERMATOSES | Beiersdorf Aktiengesellschaft (DE) | 1995-12-27 | — | — | EP | claimed |
| WO-1994021245-A1 | USE OF CARNOSINE OR A COMBINATION WITH UROCANIC ACID FOR TREATMENT OF PHOTODERMATOSES | BEIERSDORF AG (DE) | 1994-09-29 | — | — | WO | claimed |
| US-11420943-B2 | Peptide derivatives and therapeutic activity thereof | FLAMMA S.P.A. (IT) | 2022-08-23 | — | — | US | disclosed |
| EP-3732165-B1 | PEPTIDE DERIVATIVES AND THERAPEUTIC ACTIVITY THEREOF | FLAMMA SPA (IT) | 2022-08-17 | — | — | EP | disclosed |
| US-20200361875-A1 | PEPTIDE DERIVATIVES AND THERAPEUTIC ACTIVITY THEREOF | FLAMMA S.P.A. (IT) | 2020-11-19 | — | — | US | disclosed |
| EP-0688210-B1 | USE OF CARNOSINE IN COMBINATION WITH UROCANIC ACID FOR TREATMENT OF PHOTODERMATOSES | BEIERSDORF AG (DE) | 2004-02-25 | — | — | EP | disclosed |
| EP-0688210-A1 | USE OF CARNOSINE OR A COMBINATION WITH UROCANIC ACID FOR TREATMENT OF PHOTODERMATOSES | Beiersdorf Aktiengesellschaft (DE) | 1995-12-27 | — | — | EP | disclosed |
| WO-1994021245-A1 | USE OF CARNOSINE OR A COMBINATION WITH UROCANIC ACID FOR TREATMENT OF PHOTODERMATOSES | BEIERSDORF AG (DE) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361875-A1 | PEPTIDE DERIVATIVES AND THERAPEUTIC ACTIVITY THEREOF | GPX4, VIP, GPX1 | KDM4E 4773/4885ALDH1A1 1318/4885HPGD 183/4885 |
| US-11420943-B2 | Peptide derivatives and therapeutic activity thereof | GPX4, VIP, GPX1 | KDM4E 4773/4885ALDH1A1 1318/4885HPGD 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.